NurExone Biologic Ltd is developing a revolutionary biological extracellular vesicles (EV)-based technology drug platform to treat damage in the Central Nerve System (CNS). The breakthrough Exosome based technology was proven in animal studies, to have the potential to treat Spinal Cord Injuries (SCI).
The company has been granted an exclusive worldwide license to develop and commercialize the technology by the Technion, Haifa and Tel Aviv University, both located in Israel.
Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion in collaboration with Prof. Danny Offen from Tel Aviv University, tested a novel proprietary treatment using intranasal administration of EVs driven from mesenchymal stem cells loaded with siRNA PTEN targeting spinal cord lesion in rats with complete SCI. The pre-clinical results showed efficient neuron growth and significant functional recovery.